Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: Weighing the evidence

Stanley B. Cohen, Marc D. Cohen, John J. Cush, Roy M. Fleischmann, Philip J. Mease, Michael H. Schiff, Lee S. Simon, Arthur L. Weaver

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA) is a chronic, multisystem, inflammatory disorder of the joints that affects about 1% of the world population. The ultimate goals of therapy include remission of disease and prevention of joint damage. Reaching these goals has become a realistic outcome for an increasing number of patients as treatment options have expanded over the past 3 decades. In addition to older therapies, such as methotrexate (MTX), other disease modifying drugs (DMARD), and tumor necrosis factor (TNF) inhibitors, newer biologic treatments have become available. For the substantial number of patients who experience an inadequate response to standard medications, biologic response modifiers (BRM) provide an important therapeutic alternative. The availability of multiple treatment options in the absence of clear definitions or criteria for remission and inadequate response, however, makes clinical decisions about measuring outcomes, predicting response to treatment, and prescribing pharmacologic therapies challenging. In this program, distinguished rheumatologists weigh the evolving body of clinical evidence to draw sound conclusions and resolve key issues in managing inadequate response to treatment and in achieving optimal outcomes in RA.

Original languageEnglish (US)
Pages (from-to)1-30
Number of pages30
JournalJournal of Rheumatology
Volume35
Issue numberSUPPL. 81
StatePublished - Feb 1 2008

Fingerprint

Rheumatoid Arthritis
Therapeutics
Antirheumatic Agents
Joint Diseases
Methotrexate
Tumor Necrosis Factor-alpha
Joints
Pharmaceutical Preparations
Population

Keywords

  • Disease activity indices
  • Inadequate response
  • Rheumatoid arthritis
  • Treatment outcome

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Cohen, S. B., Cohen, M. D., Cush, J. J., Fleischmann, R. M., Mease, P. J., Schiff, M. H., ... Weaver, A. L. (2008). Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: Weighing the evidence. Journal of Rheumatology, 35(SUPPL. 81), 1-30.

Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis : Weighing the evidence. / Cohen, Stanley B.; Cohen, Marc D.; Cush, John J.; Fleischmann, Roy M.; Mease, Philip J.; Schiff, Michael H.; Simon, Lee S.; Weaver, Arthur L.

In: Journal of Rheumatology, Vol. 35, No. SUPPL. 81, 01.02.2008, p. 1-30.

Research output: Contribution to journalReview article

Cohen, SB, Cohen, MD, Cush, JJ, Fleischmann, RM, Mease, PJ, Schiff, MH, Simon, LS & Weaver, AL 2008, 'Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: Weighing the evidence', Journal of Rheumatology, vol. 35, no. SUPPL. 81, pp. 1-30.
Cohen, Stanley B. ; Cohen, Marc D. ; Cush, John J. ; Fleischmann, Roy M. ; Mease, Philip J. ; Schiff, Michael H. ; Simon, Lee S. ; Weaver, Arthur L. / Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis : Weighing the evidence. In: Journal of Rheumatology. 2008 ; Vol. 35, No. SUPPL. 81. pp. 1-30.
@article{8ab4e018592745d6aae288824af13276,
title = "Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: Weighing the evidence",
abstract = "Rheumatoid arthritis (RA) is a chronic, multisystem, inflammatory disorder of the joints that affects about 1{\%} of the world population. The ultimate goals of therapy include remission of disease and prevention of joint damage. Reaching these goals has become a realistic outcome for an increasing number of patients as treatment options have expanded over the past 3 decades. In addition to older therapies, such as methotrexate (MTX), other disease modifying drugs (DMARD), and tumor necrosis factor (TNF) inhibitors, newer biologic treatments have become available. For the substantial number of patients who experience an inadequate response to standard medications, biologic response modifiers (BRM) provide an important therapeutic alternative. The availability of multiple treatment options in the absence of clear definitions or criteria for remission and inadequate response, however, makes clinical decisions about measuring outcomes, predicting response to treatment, and prescribing pharmacologic therapies challenging. In this program, distinguished rheumatologists weigh the evolving body of clinical evidence to draw sound conclusions and resolve key issues in managing inadequate response to treatment and in achieving optimal outcomes in RA.",
keywords = "Disease activity indices, Inadequate response, Rheumatoid arthritis, Treatment outcome",
author = "Cohen, {Stanley B.} and Cohen, {Marc D.} and Cush, {John J.} and Fleischmann, {Roy M.} and Mease, {Philip J.} and Schiff, {Michael H.} and Simon, {Lee S.} and Weaver, {Arthur L.}",
year = "2008",
month = "2",
day = "1",
language = "English (US)",
volume = "35",
pages = "1--30",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "SUPPL. 81",

}

TY - JOUR

T1 - Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis

T2 - Weighing the evidence

AU - Cohen, Stanley B.

AU - Cohen, Marc D.

AU - Cush, John J.

AU - Fleischmann, Roy M.

AU - Mease, Philip J.

AU - Schiff, Michael H.

AU - Simon, Lee S.

AU - Weaver, Arthur L.

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Rheumatoid arthritis (RA) is a chronic, multisystem, inflammatory disorder of the joints that affects about 1% of the world population. The ultimate goals of therapy include remission of disease and prevention of joint damage. Reaching these goals has become a realistic outcome for an increasing number of patients as treatment options have expanded over the past 3 decades. In addition to older therapies, such as methotrexate (MTX), other disease modifying drugs (DMARD), and tumor necrosis factor (TNF) inhibitors, newer biologic treatments have become available. For the substantial number of patients who experience an inadequate response to standard medications, biologic response modifiers (BRM) provide an important therapeutic alternative. The availability of multiple treatment options in the absence of clear definitions or criteria for remission and inadequate response, however, makes clinical decisions about measuring outcomes, predicting response to treatment, and prescribing pharmacologic therapies challenging. In this program, distinguished rheumatologists weigh the evolving body of clinical evidence to draw sound conclusions and resolve key issues in managing inadequate response to treatment and in achieving optimal outcomes in RA.

AB - Rheumatoid arthritis (RA) is a chronic, multisystem, inflammatory disorder of the joints that affects about 1% of the world population. The ultimate goals of therapy include remission of disease and prevention of joint damage. Reaching these goals has become a realistic outcome for an increasing number of patients as treatment options have expanded over the past 3 decades. In addition to older therapies, such as methotrexate (MTX), other disease modifying drugs (DMARD), and tumor necrosis factor (TNF) inhibitors, newer biologic treatments have become available. For the substantial number of patients who experience an inadequate response to standard medications, biologic response modifiers (BRM) provide an important therapeutic alternative. The availability of multiple treatment options in the absence of clear definitions or criteria for remission and inadequate response, however, makes clinical decisions about measuring outcomes, predicting response to treatment, and prescribing pharmacologic therapies challenging. In this program, distinguished rheumatologists weigh the evolving body of clinical evidence to draw sound conclusions and resolve key issues in managing inadequate response to treatment and in achieving optimal outcomes in RA.

KW - Disease activity indices

KW - Inadequate response

KW - Rheumatoid arthritis

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=39549084962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39549084962&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:39549084962

VL - 35

SP - 1

EP - 30

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - SUPPL. 81

ER -